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In the clutches of proteoglycans: how does heparan 
sulfate regulate FGF binding? 
Fibroblast growth factors and their receptors bind to heparan sulfate glycosaminoglycans. 
This is thought to promote ligand-receptor binding and enhance signaling by promoting 
receptor multimerization. Synthetic mimetics designed to occupy these binding sites may 
provide the means to understand and to regulate FGF signaling. 
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Members of the fibroblast growth factor (FGF) family, 
which now includes nine related polypeptides, are 
unified by an affinity for heparan sulfate, with estimated 
K, values of l-100 nM [1,2]. The affinity for heparan 
sulfate was initially discovered due to tight binding of 
FGF-2 to heparin, a mast cell product that is a close 
cousin of the heparan sulfate glycosaminoglycans that are 
found attached to core proteins at the periphery of all 
adherent cells. Once referred to as the ‘heparin-binding’ 
growth factor family, the FGFs now share this distinction 
with a number of other growth factors 
A critical feature of the FGF binding to heparan sulfate is 
that it is central to FGF signaling. As is known for most 
other growth factors, FGFs signal by activating a receptor 
tyrosine kinase (RTK), which initiates a phosphorylation 
cascade within the cell that culminates in multiple cellular 
outcomes [l]. Unlike most other growth factors, however, 
the signaling complex that assembles at the cell surface 
includes heparan sulfate. Heparan sulfate-binding sites 
have been identified on the FGF and on the RTK and the 
participation of heparan sulfate in the interaction between 
FGF and its receptor has repercussions on effective recep- 
tor activation [3,4].The participation of heparan sulfate in 
this signaling has attracted the attention of scientists inter- 
ested in throwing a monkey wrench into the works.Their 
reasoning is that the correct assembly of this complex may 
be disrupted by heparan sulfates that almost, but do not 
quite, fit. This may occur naturally in biological systems, 
where the sulfation of heparan sulfate and thus its ability 
to appropriately recognize domains on the FGF and the 
receptor may vary. Researchers using chemically modified 
heparins hope to identify potent mimetics that can regu- 
late abnormal FGF signaling in diseases such as atheroscle- 
rosis or in neoplasia by, for example, inhibiting the 
angiogenesis that supports the growth of solid tumors. 
The FGFs (Table 1) are characterized by their prototypes, 
FGFs 1 and 2, which have roles in numerous tissues and in 
early development [l]. The FGF family is an enigma in 
many ways, not the least of which is the issue of how a 
signal is generated.The idea that they may signal by recep- 
tor transphosphorylation is attractive; in this model, RTKs 
are caused to form dimers or multimers by ligand binding 
and, once brought into proximity, actively phosphorylate 
one another. The phosphorylated tyrosines then act as a 
scaffold for the assembly of an aggregate of cytosolic 
signaling molecules. As FGFs and their receptors exist as 
monomers, however, it is unclear how they form multi- 
mers and as yet unproved that the receptors must dimerize 
in order to signal. 
FCF receptor tyrosine kinases (RTKs) 
The FGFs initiate a cell surface signal by binding to a 
family of RTKs (FGFRl-4), represented by four family 
members and splicing variants [5]. The receptors activate 
multiple signaling pathways and the stimulation of spe- 
cific pathways can be uncoupled by mutating specific 
tyrosines in the cytoplasmic domain [6].Thus, regulation 
of transphosphorylation by manipulating the dimeriza- 
tion process may be a potential means of fine-tuning the 
response to FGE 
In their extracellular domains, these receptors contain 
immunoglobulin (Ig)-like loop domains that place them 
in the Ig superfamily of receptors. All four receptor 
types contain three Ig domains, whereas FGFRs l-3 
also display splice variants lacking the distal Ig loop 
(loop I). In addition, Ig loop III, proximal to the plasma 
membrane, displays splicing variation that dramatically 
affects affinity for specific FGF family members. This is 
perhaps most apparent for FGFR-2, where splicing vari- 
ation in the latter half of the third Ig loop converts an 
affinity of FGFR-2 for either FGF-1 or FGF-2 into a 
Table 1. Numerical designation for members of the FGF family. 
Number Alternate name(s) 
FGF-1 
FGF-2 
FCF-3 
FGF-4 
FGF-5 
FGF-6 
FGF-7 
FGF-8 
FGF-9 
Acidic FCF 
Basic FGF 
int-2 
hst, k-FGF 
- 
- 
KGF 
AIGF 
GAF 
AIGF, Androgen-induced growth factor; GAF, glia-activating 
factor; KGF, keratinocyte growth factor. 
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keratinocyte growth factor (KGF) receptor, with much 
lowered affinity for FGFs 1 and 2 [7]. 
Another feature of the extracellular domain of the FGF 
RTKs is a heparan sulfate binding region (Fig. 1). This 
is located just distal to the second Ig loop and is con- 
tained in all spliced forms of the RTKs [S]. Modeling 
of the receptor conformation suggests that this domain 
participates in anchoring heparan sulfate and FGF 
within a receptor dimer [9]. A region that contains the 
heparan sulfate domain, Ig-loop II, the interloop region 
between loops II and III and the distal portion of loop 
III is protected from tryptic digestion when bound by 
heparan sulfate [lo]. This region constitutes the 
minimal portion of the receptor that will bind FGE The 
remaining section of loop III undergoes splicing varia- 
tion and has a major role in determining specificity of 
FGFRs for specific FGFs [5,10] 
N-terminus 
Loop II 
Loop III 
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Fig. 1. Model of the extracellular, FGF-binding region of the FGF 
receptor tyrosine kinase. Shown are the second and third lg- 
loops of the extracellular domain, with the heparin-binding 
region shown in solid red. The dotted red region, including the 
heparin-binding domain, is protected by heparan sulfate from 
tryptic digestion; this fragment has been shown by Wang et al. 
[IO] to represent the minimal binding region for FGF. The blue 
region, which includes the variably spliced lllc domain of loop III 
influences receptor specificity. Adapted from Wang et al. [I 01. 
- 
Heparan sulfate proteoglycans: regulators of receptor function 
Heparan sulfate proteoglycans are found in the extra- 
cellular matrix adjacent to cell surfaces and as integral 
components of the plasma membrane [l 1,121. Perlecan is 
a ubiquitous component of basement membranes and is 
also secreted into the matrix surrounding stromal cells. 
On cell membranes, the syndecans and betaglycan are 
present as transmembrane proteins, together with a 
group of phosphatidylinositol-linked heparan sulfate pro- 
teoglycans. These proteoglycans present a dense array of 
heparan sulfate chains that bind a variety of matrix com- 
ponents and growth factors. The binding to matrix is 
believed to be important in matrix organization and in 
the formation of focal contacts (sites of adhesion 
between the cell and its substratum). 
Heparan sulfate glycosaminoglycans: specificity within 
the polymer? 
The binding of heparan sulfate to its ligands is influenced 
by the construction of the glycosaminoglycan chain 
[11,12]. Synthesis begins with the synthesis of a tetra- 
saccharide linkage region on the core protein to which is 
added a repeating l-4 glycosidically-linked copolymer of 
D-glucuromc acid and N-acetyl-D-ghrcosamine.The chain 
is then subjected to enzymatic modifications as the pro- 
teoglycan passes through the Golgi apparatus, culminating 
in a highly modified polyanion; at its greatest extent, the 
modified polymer displays disaccharides where glu- 
curonate has been epimerized to iduronate, and sulfate 
residues have been added at several sitesThe repercussions 
of these modifications are still not fully understood, but 
recent findings suggest that binding sites for specific 
ligands are present within the chain. The chains can be 
digested with heparinases that cleave at discrete sites, not 
unlike the use of restriction enzymes to examine the fre- 
quency of specific sites within a DNA strand; unfortu- 
nately this technique is limited to two or possibly three 
useful enzymes. Heparan sulfate or heparin fragments 
bearing different patterns of modifications can be derived 
in this manner, however, and some of these fragments 
display affinity for defined ligands [ 13,141. Additionally 
these fragments can be desulfated by chemical means to 
demonstrate the requirement for specific sulfate groups in 
the binding [15-171. A further intriguing finding is that 
the modifications are likely to be cell type specific; isola- 
tion of a single heparan sulfate proteoglycan from different 
cell types and analysis of its chain structure by heparinase 
cleavage has shown differences in the modification pattern 
[18]. And it is quite possible that these modifications are 
also proteoglycan-specific. 
Is FGF’s affinity for heparan sulfate its Achilles’ heel? 
From the time of their discovery, the FGFs have been 
known to have an affinity for heparan sulfate.The classical 
method for purifying FGFs is on heparin affinity columns 
where elution requires up to 1.5 M NaCl [2]. At cell sur- 
faces, more than lo6 binding sites for FGF exist within 
the meshwork of heparan sulfate.This serves to limit the 
diffusion of FGF but is also argued to directly augment 
FGF binding to its RTK.The binding of FGFs to heparan 
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sulfates shows a considerable degree of specificity. FGF-2 
binding depends on specific modifications ; the important 
modifications appear to differ for FGF-1 and FGF-4 [15]. 
Fragmentation of heparan sulfate with heparinases allows 
the isolation of a highly active fragment for FGF-2 that 
displays high amounts of iduronosyl-2-O-sulfate; calcula- 
tions suggest that roughly one such site may occur per 
heparan sulfate chain [13]. But these modifications may 
not occur on all proteoglycans or in all tissues. It has been 
argued, for example, that the heparan sulfate present on 
perlecan of human lung fibroblasts rather than that of cell 
surface forms of heparan sulfate proteoglycans is responsi- 
ble for FGF binding and activation [19]. Indeed, the 
heparan sulfate chains present on some proteoglycans 
appear to bind FGF-2, but actually inhibit its activity by 
depriving it from heparan sulfates that would augment its 
activity Presumably, these inhibitory heparan sulfates fail 
to participate in formation of a signaling complex at the 
cell surface. A similar example of proteoglycan specificity 
is derived from the embryonic neuroepithelium, where 
the specificity of a heparan sulfate proteoglycan changes 
during development in unison with a change in FGF 
expression [20]. 
Formation of the receptor/FGF/heparan sulfate complex 
Modeling of the binding of FGF to its receptor has taken 
many forms, from activity analyses using truncated or 
modified forms of the participants to crosslinking studies 
and physical chemical imaging. The central issues are an 
understanding of how the receptor assimilates FGF into 
a high affinity complex and how subsequent signaling is 
initiated.These two issues share a common uncertainty, 
namely, does the FGF and/or the receptor need to 
dimerize and how might this be accomplished? Physical 
mapping of FGF on a heparin glycosaminoglycan 
demonstrates that a single FGF may occupy as few as five 
saccharides within a chain of over twenty [16,17].Thus, 
multiple FGFs binding to a single chain would achieve 
‘dimerization’ of the growth factor. Use of high concen- 
trations of FGF together with heparan sulfates show that 
the FGF can be cross-linked into dimers [21]. Similarly, a 
fraction of the FGF receptors appear to be dimerized at 
the cell surface by cross-linking methods [22]. It remains 
to be formally shown how these dimers are assembled 
and that they are responsible for all signaling, however. 
Using FGF-2 and FGFRl as models, important domains 
in FGF-2 have been identified that mediate its binding 
and activity [9,23] (Fig. 2). One is a hydrophobic region 
that binds the receptor and is composed ofY24, R44, 
NlOl,Y103, L140 and M142, withY24,Y103 and L140 
being especially critical. These latter three amino acids 
are highly conserved in the FGF family and are likely to 
represent an important receptor-binding domain. A 
second domain that binds the receptor is a loop compris- 
ing amino acids 106-115; mutations in amino acids 
KllO,Ylll and W114 or removal of this loop dramati- 
cally influence FGF activity [24]. This loop has a lower 
affinity for the receptor and is postulated in one model 
to play a role in receptor dimerization. Mutations within 
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Fig. 2. Model of FGF-2 showing important binding domains. Two 
important classes of binding domains have been proposed within 
the growth factor. A primary receptor-binding domain is com- 
prised of amino acids Y24, R44, NlOl, Y103, L140 and Ml42 
(shown in dark blue). A secondary receptor binding domain 
(Kl IO, Yl 11 and WI 14) is in light blue. The primary heparan- 
sulfate-binding domain is shown in red (N27, K119, R120, K125, 
K129, Q134 and K135). Two secondary sites (shown in dark and 
light green) have been identified by binding di- or trisaccharides 
and are proposed by Ornitz et al. [21] to take part in bFGF dimer- 
ization when occupied by the oligosaccharides. Thus, the region 
shown in dark green (R60, G61, E96 and R97) is proposed to 
interact with a second bFGF via the region shown in light green 
(R72, K77, R81 and K86). Adapted from Ericksson et al. [27]. 
this domain do not interfere with receptor binding per se, 
but do reduce activity [24]. The third domain is the 
heparin (heparan sulfate) binding domain that encom- 
passes amino acids N27, K119, R120, K125, K129, K135 
and Q134 (8,23); these amino acids comprise a cationic 
site that binds heparin fragments a short as five sugars, 
but enhancement of activity is seen as the length of these 
fragments approaches 12 sugars [14,15]. 
The identification of these domains provides insight 
into important binding events when FGF-2 binds to 
FGFRl: receptor binding to FGF, receptor binding to 
heparan sulfate, FGF binding to heparan sulfate, the 
complex of FGF/heparan sulfate binding to receptor 
and, finally, a second receptor with or without another 
FGF binding to this assembly.This latter event does not 
appear to occur in the absence of heparin or heparan 
sulfate and failure of this binding to occur dramatically 
reduces FGF signaling [3]. The role of the heparan 
sulfate is likely to be two-fold: first, to mask positive 
charges on the FGF and its receptor, allowing them to 
approach each other, and, second, to provide anchorage 
between molecules in the complex. Indeed, models of 
FGF:receptor interaction suggest that a heparan sulfate 
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consisting of lo-12 saccharides would anchor them 
together [9]. Heparin fragments of less than this size are 
usually found to be inhibitory, presumably because they 
occupy FGF-2 but cannot participate effectively in 
facilitating receptor binding. 
It is interesting to speculate how heparan sulfates longer 
than 12 saccharides, or proteoglycans bearing multiple 
chains, would help to generate multimers of these 
FGF:receptor complexes. Such complexes may be neces- 
sary for efficient transphosphorylation and their forma- 
tion may stabilize FGF binding. That is, the strength of 
these interactions may depend on the degree to which a 
‘complete’ complex is formed. This speculation is intrigu- 
ing due to the current interest in the ‘strength of signal’ 
hypothesis extended for other growth factors such as epi- 
dermal growth factor (EGF) and nerve growth factor 
(NGF) [25].This hypothesis suggests that the strength of 
the growth factor signal, which is a mnction of the degree 
to which receptor signaling is sustained, determines 
which intracellular pathways can be activated. One model 
for this is that the signal may need to be strong enough to 
overcome the intracellular phosphatases necessary to keep 
the signal turned off. Thus, the amount of time that FGF 
is resident on its receptor and the retention of the recep- 
tor as a signaling entity would determine the strength of 
the signal. Heparan sulfate proteoglycans may have a very 
interesting role in such signaling. 
A final variable to be considered is multiple configura- 
tions of the FGF receptor.The heparin-binding domain 
appears to be variably exposed in splice variants that 
display either two or three Ig loops. When the variably 
expressed Ig loop I is present, it can interact with loop 
11, masking the heparin-binding site on the receptor and 
influencing the participation of heparan sulfate in the 
binding of FGF-1 [26]. 
Oligosaccharides as mediators of FCF action 
Pinpointing several important heparan sulfate binding 
sites within the FGF signaling complex suggests appeal- 
ing notions for the design of signaling competitors. 
These sites may either be bona jde sites on the FGF or 
receptor which normally participate in complex forma- 
tion, or be hidden sites that prevent complex formation 
when bound by small synthetic oligosaccharides. 
Maccarana et al. [16] described a minimal pentasaccha- 
ride of heparin that appears capable of binding FGF-2, 
although longer fragments appear likely to participate in 
signaling. However, Ornitz et al. [21] have now described 
smaller synthetic di- and trisaccharides that either stimu- 
late or inhibit FGF activity on lymphoid cells transfected 
with the cDNA for FGFRl. These cells are devoid of 
endogenous heparan sulfate proteoglycans and respond 
to the FGF only when presented with exogenous 
heparan sulfate.Two new sites are described on FGF-2 
(Fig. 2); sites which when occupied by small synthetic 
heparin fragments may promote the dimerization of two 
FGFs. This is of interest for several reasons. First, it iden- 
tifies sites that may be part of an important mechanism 
for FGF signaling, although it remains to be shown that 
native heparan sulfates would bind to these regions. 
Second, it demonstrates that synthetic oligosaccharides 
or their homologs can bind to specific sites within FGF, 
potentially affecting activity. It is intriguing to note that 
the ability of the oligos to promote FGF signaling does 
not necessarily correlate with their ability to promote 
binding of FGF to a soluble form of receptor. 
Comparison of a di- and trisaccharide that promote 
equivalent binding of FGF to receptor shows that the 
trisaccharide is lo-fold more effective at promoting 
mitogenic stimulation. The explanation for this may lie 
in the several potential heparin binding sites on the FGF 
and receptor.Thus, small fragments may be envisioned to 
facilitate receptor signaling either by enhancing the affin- 
ity of FGF binding to receptor, or by enhancing the 
ability of two FGFs to dimerize. One might speculate 
that heparan sulfate proteoglycans at the cell surface par- 
ticipate in both events, leading to the formation of a 
stable, multimeric complex that carries out signaling. 
Equally plausible is that oligosaccharides that bind but 
fail to ‘fit’ would succeed in preventing one or more of 
these interactions.This leads to the speculation that small 
heparinoids may successfully be used to either com- 
pletely inhibit the formation of such a complex, or even 
manipulate the stability of the complex formed, and thus 
the activity of the signaling pathway. 
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